 | • レポートコード：MRC20A42 • 出版社/出版日：Transparency Market Research / 2020年10月30日 • レポート形態：英文、PDF、183ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは、ヒト用ワクチンの世界市場について調査し、序論、仮定/調査手法、エグゼクティブサマリー、市場概要、キーインサイト、ワクチン別（結合型、組換え型、不活化、弱毒生、その他）分析、製品別分析、流通チャンネル別分析、年齢層別分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東/アフリカ）分析、競争状況などを掲載しています。 ・序論 ・仮定/調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・ヒト用ワクチンの世界市場規模：ワクチン別（結合型、組換え型、不活化、弱毒生、その他） ・ヒト用ワクチンの世界市場規模：製品別 ・ヒト用ワクチンの世界市場規模：流通チャンネル別 ・ヒト用ワクチンの世界市場規模：年齢層別 ・ヒト用ワクチンの世界市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東/アフリカ） ・競争状況 |
Global Human Vaccine Market – Scope of Report
TMR’s report on the global human vaccine market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators of the market during the forecast period from 2019 to 2027. The report provides revenue of the global human vaccine market for the period 2017–2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global human vaccine market during the forecast period.
The report has been prepared after an extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global human vaccine market.
Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomenon in the global human vaccine market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global human vaccine market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global human vaccine market.
The report delves into the competitive landscape of the global human vaccine market. Key players operating in the global human vaccine market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global human vaccine market that have been profiled in this report.
Key Questions Answered in Global Human vaccine Market Report
What is the scope of growth of product companies in the global human vaccine market?
What will be the Y-o-Y growth of the global human vaccine market between 2019 and 2027?
What is the influence of changing trends in technologies on the global human vaccine market?
Will North America continue to be the most profitable market for human vaccine providers?
Which factors are anticipated to hamper the growth of the global human vaccine market during the forecast period?
Which are the leading companies in the global human vaccine market?
Research Methodology
A unique research methodology has been utilized by TMR to conduct comprehensive research on the growth of the global human vaccine market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.
Secondary methods referred to by analysts during the production of the global human vaccine market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR’s study on the human vaccine market as primary methods.
These primary and secondary methods have provided exclusive information during interviews, which serves as a validation from the human vaccine market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global human vaccine market with accuracy. The study also uses the top-down approach to assess the revenues for each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on future prospects of the global human vaccine market more reliably and accurately.
Regional Segmentation of Human vaccine Market
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of Middle East & Africa
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Human Vaccine Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Human Vaccine Market Analysis and Forecasts, 2018–2030
5. Key Insights
5.1. Product Overview
5.2. Key Industry Developments
5.3. Emerging Trends in Human Vaccines Market
6. Global Human Vaccine Market Analysis and Forecasts, By Vaccine
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Vaccine, 2018–2030
6.3.1. Conjugate
6.3.2. Recombinant
6.3.3. Inactivated
6.3.4. Combination
6.3.5. Attenuated
6.3.6. Others
6.4. Market Attractiveness By Vaccine
7. Global Human Vaccine Market Analysis and Forecasts, By Product
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Product, 2018–2030
7.3.1. Pneumococcal
7.3.2. Influenza
7.3.3. Hepatitis
7.3.4. HPV
7.3.5. Meningococcal
7.3.6. Rotavirus
7.3.7. Measles and Rubella
7.3.8. Typhoid
7.3.9. Combination
7.3.10. Others
7.4. Market Attractiveness By Product
8. Global Human Vaccine Market Analysis and Forecasts, By Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Distribution Channel, 2018–2030
8.3.1. Hospital Pharmacies
8.3.2. Drugstores
8.3.3. Others
8.4. Market Attractiveness By Distribution Channel
9. Global Human Vaccine Market Analysis and Forecasts, By Age Group
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast By Age Group, 2018–2030
9.3.1. Pediatrics
9.3.2. Adolescents
9.3.3. Adults
9.3.4. Geriatrics
9.4. Market Attractiveness By Age Group
10. Global Human Vaccine Market Analysis and Forecasts, By Region
10.1. Key Findings
10.2. Market Value Forecast By Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness By Region
11. North America Human Vaccine Market Analysis and Forecast
11.1. Introduction
11.2. Market Value Forecast By Vaccine, 2018–2030
11.2.1. Conjugate
11.2.2. Recombinant
11.2.3. Inactivated
11.2.4. Combination
11.2.5. Attenuated
11.2.6. Others
11.3. Market Value Forecast By Product, 2018–2030
11.3.1. Pneumococcal
11.3.2. Influenza
11.3.3. Hepatitis
11.3.4. HPV
11.3.5. Meningococcal
11.3.6. Rotavirus
11.3.7. Measles and Rubella
11.3.8. Typhoid
11.3.9. Combination
11.3.10. Others
11.4. Market Value Forecast By Distribution Channel, 2018–2030
11.4.1. Hospital Pharmacies
11.4.2. Drugstores
11.4.3. Others
11.5. Market Value Forecast By Age Group, 2018–2030
11.5.1. Pediatrics
11.5.2. Adolescents
11.5.3. Adults
11.5.4. Geriatrics
11.6. Market Value Forecast By Country, 2018–2030
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Vaccine
11.7.2. By Product
11.7.3. By Distribution Channel
11.7.4. By Age Group
11.7.5. By Country
12. Europe Human Vaccine Market Analysis and Forecast
12.1. Introduction
12.2. Market Value Forecast By Vaccine, 2018–2030
12.2.1. Conjugate
12.2.2. Recombinant
12.2.3. Inactivated
12.2.4. Combination
12.2.5. Attenuated
12.2.6. Others
12.3. Market Value Forecast By Product, 2018–2030
12.3.1. Pneumococcal
12.3.2. Influenza
12.3.3. Hepatitis
12.3.4. HPV
12.3.5. Meningococcal
12.3.6. Rotavirus
12.3.7. Measles and Rubella
12.3.8. Typhoid
12.3.9. Combination
12.3.10. Others
12.4. Market Value Forecast By Distribution Channel, 2018–2030
12.4.1. Hospital Pharmacies
12.4.2. Drugstores
12.4.3. Others
12.5. Market Value Forecast By Age Group, 2018–2030
12.5.1. Pediatrics
12.5.2. Adolescents
12.5.3. Adults
12.5.4. Geriatrics
12.6. Market Value Forecast By Country, 2018–2030
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Vaccine
12.7.2. By Product
12.7.3. By Distribution Channel
12.7.4. By Age Group
12.7.5. By Country
13. Asia Pacific Human Vaccine Market Analysis and Forecast
13.1. Introduction
13.2. Market Value Forecast By Vaccine, 2018–2030
13.2.1. Conjugate
13.2.2. Recombinant
13.2.3. Inactivated
13.2.4. Combination
13.2.5. Attenuated
13.2.6. Others
13.3. Market Value Forecast By Product, 2018–2030
13.3.1. Pneumococcal
13.3.2. Influenza
13.3.3. Hepatitis
13.3.4. HPV
13.3.5. Meningococcal
13.3.6. Rotavirus
13.3.7. Measles and Rubella
13.3.8. Typhoid
13.3.9. Combination
13.3.10. Others
13.4. Market Value Forecast By Distribution Channel, 2018–2030
13.4.1. Hospital Pharmacies
13.4.2. Drugstores
13.4.3. Others
13.5. Market Value Forecast By Age Group, 2018–2030
13.5.1. Pediatrics
13.5.2. Adolescents
13.5.3. Adults
13.5.4. Geriatrics
13.6. Market Value Forecast By Country, 2018–2030
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Vaccine
13.7.2. By Product
13.7.3. By Distribution Channel
13.7.4. By Age Group
13.7.5. By Country
14. Latin America Human Vaccine Market Analysis and Forecast
14.1. Introduction
14.2. Market Value Forecast By Vaccine, 2018–2030
14.2.1. Conjugate
14.2.2. Recombinant
14.2.3. Inactivated
14.2.4. Combination
14.2.5. Attenuated
14.2.6. Others
14.3. Market Value Forecast By Product, 2018–2030
14.3.1. Pneumococcal
14.3.2. Influenza
14.3.3. Hepatitis
14.3.4. HPV
14.3.5. Meningococcal
14.3.6. Rotavirus
14.3.7. Measles and Rubella
14.3.8. Typhoid
14.3.9. Combination
14.3.10. Others
14.4. Market Value Forecast By Distribution Channel, 2018–2030
14.4.1. Hospital Pharmacies
14.4.2. Drugstores
14.4.3. Others
14.5. Market Value Forecast By Age Group, 2018–2030
14.5.1. Pediatrics
14.5.2. Adolescents
14.5.3. Adults
14.5.4. Geriatrics
14.6. Market Value Forecast By Country, 2018–2030
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Vaccine
14.7.2. By Product
14.7.3. By Distribution Channel
14.7.4. By Age Group
14.7.5. By Country
15. Middle East & Africa Human Vaccine Market Analysis and Forecast
15.1. Introduction
15.2. Market Value Forecast By Vaccine, 2018–2030
15.2.1. Conjugate
15.2.2. Recombinant
15.2.3. Inactivated
15.2.4. Combination
15.2.5. Attenuated
15.2.6. Others
15.3. Market Value Forecast By Product, 2018–2030
15.3.1. Pneumococcal
15.3.2. Influenza
15.3.3. Hepatitis
15.3.4. HPV
15.3.5. Meningococcal
15.3.6. Rotavirus
15.3.7. Measles and Rubella
15.3.8. Typhoid
15.3.9. Combination
15.3.10. Others
15.4. Market Value Forecast By Distribution Channel, 2018–2030
15.4.1. Hospital Pharmacies
15.4.2. Drugstores
15.4.3. Others
15.5. Market Value Forecast By Age Group, 2018–2030
15.5.1. Pediatrics
15.5.2. Adolescents
15.5.3. Adults
15.5.4. Geriatrics
15.6. Market Value Forecast By Country, 2018–2030
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Vaccine
15.7.2. By Product
15.7.3. By Distribution Channel
15.7.4. By Age Group
15.7.5. By Country
16. Competition Landscape
16.1. Market Share Analysis By Company (2019)
16.2. Company Profiles
16.2.1. AstraZeneca plc
16.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.1.2. Growth Strategies
16.2.1.3. SWOT Analysis
16.2.2. Bavarian Nordic
16.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.2.2. Growth Strategies
16.2.2.3. SWOT Analysis
16.2.3. Bharat Biotech
16.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.3.2. Growth Strategies
16.2.3.3. SWOT Analysis
16.2.4. CSL Limited
16.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.4.2. Growth Strategies
16.2.4.3. SWOT Analysis
16.2.5. Emergent BioSolutions, Inc.
16.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.5.2. Growth Strategies
16.2.5.3. SWOT Analysis
16.2.6. GlaxoSmithKline plc.
16.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.6.2. Growth Strategies
16.2.6.3. SWOT Analysis
16.2.7. Johnson & Johnson
16.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.7.2. Growth Strategies
16.2.7.3. SWOT Analysis
16.2.8. Merck & Co, Inc.
16.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.8.2. Growth Strategies
16.2.8.3. SWOT Analysis
16.2.9. Mymetics
16.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.9.2. Growth Strategies
16.2.9.3. SWOT Analysis
16.2.10. Novartis AG
16.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.10.2. Growth Strategies
16.2.10.3. SWOT Analysis
16.2.11. Pfizer, Inc.
16.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.11.2. Growth Strategies
16.2.11.3. SWOT Analysis
16.2.12. Sanofi S.A.
16.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.12.2. Growth Strategies
16.2.12.3. SWOT Analysis
16.2.13. Shenzhen Kangtai Biological Products Co., Ltd.
16.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.13.2. Growth Strategies
16.2.13.3. SWOT Analysis
16.2.14. Takeda Pharmaceutical Company Limited
16.2.14.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.14.2. Growth Strategies
16.2.14.3. SWOT Analysis
List of TablesTable 01 Global Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2019–2027
Table 02 Global Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2019–2027
Table 03 Global Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2019–2027
Table 04 Global Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2019–2027
Table 05 Global Human Vaccines Market Size (US$ Mn) Forecast, by Region, 2019–2027
Table 06 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2019–2027
Table 07 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2019–2027
Table 08 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2019–2027
Table 09 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2019–2027
Table 10 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2019–2027
Table 11 North America Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2019–2027
Table 12 North America Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2019–2027
Table 13 North America Human Vaccines Market Size (US$) Forecast, by Vaccine Type, 2019–2027
Table 14 North America Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2019–2027
Table 15 North America Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2019–2027
Table 16 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2019–2027
Table 17 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2019–2027
Table 18 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2019–2027
Table 19 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2019–2027
Table 20 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2019–2027
Table 21 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2019–2027
Table 22 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2019–2027
Table 23 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2019–2027
Table 24 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2019–2027
Table 25 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2019–2027
Table 26 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2019–2027
Table 27 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2019–2027
Table 28 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2019–2027
Table 29 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2019–2027
Table 30 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2019–2027